Granulomatosis with polyangiitis (Wegener's) (GPA) and microscopic polyangiitis (MPA) are 2 forms of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) (1) . Advances in therapy have transformed GPA and MPA from frequently fatal conditions to chronic illnesses. The Rituximab in ANCA-Associated Vasculitis (RAVE) trial expanded standard induction treatment options for patients with AAV by demonstrating that rituximab was not inferior to cyclophosphamide for induction of remission (2, 3) . Despite the success of the trial, its results were far from ideal, as only 58% of patients in both treatment groups achieved complete remission after 6 months without prednisone, and only 36% of patients had disease in stable remission throughout the 18 months of follow-up (2) . As the medical community moves closer to the goal of treating patients using a precision medicine approach, it is plausible that therapy for AAV can be tailored to specific characteristics of individual patients.
Rituximab, a chimeric monoclonal antibody directed against the B lymphocyte-restricted cell surface protein CD20, kills B cells mainly through antibody-dependent cellmediated cytotoxicity (ADCC) (4) . ADCC is mediated through Fcg receptors (FcgR), particularly FcgRIIIa expressed on natural killer (NK) cells. Of potential clinical relevance, single-nucleotide polymorphisms (SNPs) in FcgR genes can influence the function of FcgR (5) . Studies in lymphoma (6) (7) (8) (9) , rheumatoid arthritis (10, 11) , and other autoimmune conditions (12, 13) have shown that the response to rituximab may be affected by FcgR polymorphisms.
Cyclophosphamide has been used for induction of remission in patients with AAV for almost 4 decades. Cyclophosphamide is a prodrug that requires activation (4-hydroxylation) by the hepatic cytochrome P450 (CYP) enzymes. Several CYP isoforms contribute to cyclophosphamide metabolism including CYP2B6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 (14) . Of these CYP enzymes, variants in the CYP2B6 and CYP2C19 genes appear to have the most clinically relevant effects in conditions commonly treated with cyclophosphamide, such as cancer and systemic lupus erythematosus (SLE) (15) (16) (17) (18) (19) .
To date there is no information about the effects of FcgR and CYP polymorphisms on how AAV responds to treatment with rituximab or cyclophosphamide. We therefore investigated whether functional FcgRIIa, FcgRIIb, FcgRIIIa, CYP2B6, and CYP2C19 polymorphisms that are relatively common in the general population (Table 1) are associated with therapeutic response or toxicity to specific drugs in patients from the RAVE trial.
PATIENTS AND METHODS
Patients. Patients were participants in the RAVE trial. Study design details of the RAVE trial have been reported elsewhere (2, 3) . All patients enrolled in the RAVE trial provided written informed consent for the collection and future use of biologic samples and data. Participating ethics boards approved the research. This work was approved by The Ohio State University Institutional Review Board. Disease activity was scored using the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) (20, 21) . The primary outcome of the RAVE trial, complete remission, was defined as a BVAS/WG of 0 and successful completion of the prednisone taper to 0 mg by month 6. Secondary outcomes included 1) remission, defined as a BVAS/WG of 0 during treatment with continued prednisone at ,10 mg per day; 2) time to complete remission or remission in days; 3) time to relapse in days, defined as an increase in BVAS/WG of $1 point after having achieved remission; and 4) time to B lymphocyte reconstitution in days, defined as an increase in CD191 B cells to .69 cells/mm 3 after having an initial decrease to ,10 cells/mm 3 following treatment with rituximab. SNPs for FcgR (FcgRIIa 519G.A, rs1801274; FcgRIIb 695T.C, rs1050501; FcgRIIIa 559T.G, rs396991) and CYP enzymes (CYP2B6 1459C.T, rs3211371; CYP2C19 681G.A, rs4244285) were analyzed by direct sequencing of polymerase chain reaction (PCR)-amplified genomic DNA. These genes and polymorphisms were chosen because they are relatively common in the general population and they can theoretically affect the function of their respective proteins (19, (22) (23) (24) (25) (26) (27) (28) and thereby impact the efficacy of rituximab and cyclophosphamide treatment (Table 1) . DNA samples were available from 189 of the 197 participants in the RAVE trial. Genomic DNA was extracted from peripheral blood leukocytes of EDTA-treated whole blood using Gentra Puregene Blood Kits (Qiagen). Oligonucleotide primers 0 (reverse). DNA amplification was carried out by PCR using 100 ng of DNA and a MasterCycler Gradient Thermal Cycler (Eppendorf). Amplification reactions were done in a reaction volume of 25 ml with 50 mM KCl, 20 mM Tris HCl (pH 8.4), 1.5 mM MgCl 2 , 200 mM each dATP, dCTP, dGTP, dTTP (Invitrogen), and 0.5 units PlatinumTaq DNA polymerase (Invitrogen). The cycling conditions included an initial 2 minutes of incubation at 948C to activate the Taq DNA polymerase, followed by denaturation at 948C for 30 seconds, annealing at 608C for 30 seconds, and polymerization at 728C for 30 seconds for a total of 35 cycles. PCR products were checked on 2% agarose gel to confirm a single product for direct sequencing. PCR products (5 ml) were mixed with 2 ml of ExoSAP-IT (USB) followed by incubation for 15 minutes at 378C and then 15 minutes of inactivation at 808C to remove excess dNTPs and primers. The purified products were then directly sequenced with BigDye Terminator Cycle Sequencing Chemistry (Applied Biosystems) using the same PCR primers. Sequencing was performed using a 3730 DNA Analyzer (Applied Biosystems) in the Plant-Micro Genomic facility at The Ohio State University.
Care was taken in designing the primers for FcgRII to avoid inadvertently amplifying FcgRIIC by using a forward primer that mismatched with FcgRIIC at 2 of the 3 most 3 0 nucleotide residues and at 4 total residues (University of California at Santa Cruz BLAT genome search, December 2013 assembly). Using this primer under the cycling conditions indicated, particularly annealing at 608C, results in amplification of FcgRIIb alone.
Statistical analysis. For comparison of proportions, chi-square tests were used if the number of elements in each cell was $5; Fisher's exact test was used otherwise. Logistic regression was used to assess the association of each SNP (as the predictor) with the primary outcome of complete remission or the secondary outcome of remission with continued prednisone (as responses). The time-to-event data were analyzed with Cox proportional hazard ratios (HRs). In both analyses, the following prespecified covariates were included: baseline BVAS/WG, ANCA type, and new versus relapsing disease. Model fit (calibration) was assessed using the Hosmer-Lemeshow goodness-of-fit test. When appropriate, odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated. Given the proportions observed and assuming an alpha error of 5% and a power of 90%, we were able to detect in the entire cohort an OR of 2.4 for a logistic regression analysis (binary outcome) with 1 predictor. Two-sided P values less than 0.05 were considered significant. JMP statistical software, version 10.0 (SAS Institute) was used for all data analyses.
RESULTS
DNA was sequenced from 189 RAVE trial participants, of whom 96 received rituximab and 93 were Table 2 ). The mean 6 SD time to complete remission was 171 6 4 days for patients with the FcgRIIa 519AA genotype versus 212 6 9.8 days for the combined FcgRIIa 519GG/519GA genotypes (P 5 0.001).
The association of the FcgRIIa polymorphism with time to complete remission led us to examine this SNP in cyclophosphamide-treated patients and then in the whole cohort in an effort to demonstrate that this variant specifically affected responses to rituximab treatment. Unexpectedly, we found that a larger proportion of cyclophosphamide-treated patients with the 519AA genotype achieved complete remission, and this association became stronger when the entire cohort was considered (Table 3) . Furthermore, in the entire cohort, the FcgRIIa 519AA genotype was associated with increased odds of achieving complete remission (OR 2.61 [95% CI 1.29-5.55], P 5 0.006) and with a shorter time to complete remission (HR 1.93 [95% CI 1.33-2.78], P , 0.001), even after adjustment for covariates (Table 4) .
In the entire cohort, the odds of achieving complete remission at 6 months were even higher in patients homozygous for both FcgRIIa 519A and FcgRIIIa 559G (OR 7.87 [95% CI 1.48-145], P 5 0.01; n 5 12 patients, 5 taking No significant associations were found between FcgRIIa, FcgRIIb, FcgRIIIa, and CYP2B6 polymorphisms and time to AAV relapse or time to B cell reconstitution (see Supplementary Table 4 , http://onlinelibrary.wiley.com/ doi/10.1002/art.39822/abstract). The CYP2C19 homozygous 681AA genotype was associated with more rapid B cell reconstitution than were the combined 681GG and 681GA genotypes (HR 0.14 [95% CI 0.007-0.74], P 5 0.01) in cyclophosphamide-treated patients. However, only 2 patients were homozygous, calling into question the reliability of this finding. No significant associations were identified between FcgR and CYP SNPs and the development of all adverse events, grade 3 adverse events, grade $2 leukopenia, grade $3 thrombocytopenia, or infections (data not shown).
DISCUSSION
This cohort study of AAV patients from the RAVE trial was done to evaluate the pharmacogenomic associations of FcgR and CYP enzymes with response to treatment with rituximab or cyclophosphamide, respectively. To the best of our knowledge, no previous study has assessed the role of pharmacogenomics in the therapy of AAV patients receiving rituximab or cyclophosphamide. Although we postulated that genetic background would be useful in choosing between rituximab and cyclophosphamide as the most effective induction drug for individual patients, this was not demonstrated for the polymorphisms tested. Furthermore, knowledge of patient genotypes for FcgR and CYP enzymes did not differentiate patients by time to B cell reconstitution or susceptibility to treatmentassociated side effects. Unexpectedly, however, the FcgRIIa 519AA genotype was found to predict complete response and a shorter time to complete response independently of the induction treatment used, suggesting that FcgRIIa may play a pathogenic role in AAV.
The FcgR that we studied included 2 activating receptors, FcgRIIa and FcgRIIIa, and 1 inhibitory receptor, FcgRIIb. FcgRIIa is expressed on myeloid cells, dendritic cells, and platelets, FcgRIIb is expressed on myeloid cells, dendritic cells, and B cells, and FcgRIIIa is expressed on macrophages, some monocyte subsets, and NK cells (29) . The FcgRIIa SNP 519G.A changes an arginine to a histidine at amino acid 131, the FcgRIIIa SNP 559T.G changes a phenylalanine to a valine at amino acid 158, and the FcgRIIb SNP 695T.C changes an isoleucine to a threonine at amino acid 187. These SNPs all affect protein function, with the FcgRIIa 131H variant exhibiting enhanced binding to IgG2, the FcgRIIIa 158V variant exhibiting enhanced binding to IgG1 and IgG3, and the FcgRIIb 187T variant having defective lipid raft anchoring and consequently decreased inhibitory function (28, 30) . All 3 of these polymorphisms have been reported to influence susceptibility to another autoimmune disease, SLE or lupus nephritis, likely through differences in immune complex clearance (FcgRIIa, FcgRIIIa) or immunoregulation (FcgRIIb) (for review, see ref. 31) .
Because the effects of rituximab are mediated in part through FcgR (6, 32) , it is plausible that FcgR polymorphisms may also influence the response to rituximab therapy. Indeed, rituximab efficacy has been reported to be better in patients with the FcgRIIIa 158VV genotype in the treatment of non-Hodgkin's lymphomas (33) and rheumatoid arthritis (11) . In contrast, none of these FcgR SNPs influenced the efficacy of rituximab in AAV, suggesting that these FcgR genetic variations are not important for rituximab in vasculitis. However, analysis of secondary RAVE trial outcomes showed that the homozygous FcgRIIa SNP variant (519AA) was associated with a shorter time to complete remission. Surprisingly, this association also extended to the entire cohort, including patients treated with cyclophosphamide (data not shown). Furthermore, when the entire cohort was considered (rituximab-and cyclophosphamide-treated patients), the 519AA homozygous variant and the 519AA plus FcgRIIIa 559GG homozygous genotype were also found by regression analysis to be associated with and to predict complete remission. This association is consistent with a previous observation that patients with GPA who had a combined homozygous genotype of FcgRIIa 519AA and FcgRIIIa 559GG were relatively protected from disease relapse compared to having all other combinations of FcgR genotypes (34) . FcgRIIa 519AA appears to identify an AAV phenotype with a more favorable clinical prognosis. Exploring the mechanism of this beneficial effect is beyond the scope of this investigation, but expressing the highaffinity FcgR phenotype may help suppress AAV activity by enhancing and accelerating the clearance of ANCAs or other inciting antibodies/immune complexes.
Similar to our results with rituximab and FcgR polymorphisms, we observed no effect of CYP polymorphisms on the response of AAV patients to cyclophosphamide or susceptibility to cyclophosphamide toxicity, except for an association between the CYP2C19 homozygous 681AA genotype and more rapid B cell reconstitution. As pointed out in the Results, there were only 2 patients with this homozygous variant genotype, making this conclusion tentative. In other conditions, CYP enzyme SNPs have been found to affect the response to and the toxicity of cyclophosphamide therapy. The variant CYP2C19*2 (681G.A) results in an inactive enzyme (24) , and 1 study showed that carriers of at least 1 CYP2C19*2 allele were protected against cyclophosphamide-related premature ovarian failure but that CYP2C19*2 homozygous patients with lupus nephritis who were treated with cyclophosphamide had a higher probability of developing end-stage renal disease (17) . The same study demonstrated that patients receiving pulse cyclophosphamide for the treatment of lupus nephritis who were homozygous for CYP2B6*5, a haplotype that results in decreased enzyme expression by the liver (23), also had a higher probability of developing end-stage renal disease.
These findings suggest that SNPs resulting in reduced levels of the active drug decrease the efficacy of cyclophosphamide (17) . However, other studies have not confirmed these pharmacogenomic associations in either lupus nephritis (35) or breast cancer (36) . Thus, it remains unclear whether genotyping for CYP variants is useful in deciding whether to treat an individual patient with cyclophosphamide or an alternate drug, and this may be disease specific.
This study has limitations. It is a post hoc analysis. For some of the genotypes, there were only a few patients, which prevented statistical analyses to identify significant associations. Additionally, not all known FcR and CYP SNPs were tested, so we cannot exclude the possibility that other genetic predispositions may specifically affect response to rituximab or cyclophosphamide. Finally, the lack of association of genotype with response to a specific treatment will need to be validated in an independent AAV cohort. We are optimistic that these data can be reproduced in one or more of the AAV cohorts assembled for recent clinical trials. On the other hand, the study's main strength stems from its prospective cohort assembled from a large multicenter randomized controlled trial of patients who were treated with rituximab or cyclophosphamide and followed up meticulously for clinical outcomes.
In conclusion, in this cohort study of AAV patients from the RAVE trial, there is no evidence to suggest that genotyping patients for several highprevalence and functional FcR or CYP polymorphisms will be helpful in individualizing induction therapy to either rituximab or cyclophosphamide. This is relevant information for practice and suggests that choice of therapy should mainly consider the patient's clinical context. Alternatively, FcgRIIa variants appear to identify a subgroup of patients who may be expected to achieve remission more rapidly during induction. While there does not appear to be an overt clinical need to genotype FcgRIIa for the current management of AAV, determining the mechanisms of this apparent genotype-phenotype interaction could help further our understanding of how to decide which AAV patients are suitable for routine treatment and which patients may need novel therapy.
